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ABSTRACT
Objective: The aim of the present investigation was to design gels for the topical delivery of celecoxib and evaluate with an aim to increase its 
penetration through the skin and thereby its flux.
Method: The solubility of celecoxib is shown to be increased by preparing solid dispersions (SDs) using carriers such as mannitol, polyvinylpyrrolidone 
(PVP-K30), polyethylene glycol (PEG) 6000 and urea by solvent evaporation, fusion, and coevaporation methods. In vitro release profile of all SD 
was comparatively evaluated and studied against the pure drug. The prepared SD was subjected for percent practical yield, drug content, infrared 
spectroscopy, differential scanning calorimetry analysis, X-ray diffraction studies, and scanning electron microscopy (SEM) imaging. The celecoxib gel 
was prepared using hydroxypropyl methyl cellulose (HPMC) and Carbopol containing a permeation enhancer dimethyl sulfoxide (DMSO) at different 
proportions and evaluated for drug content, pH, viscosity, spreadability, extrudability, stability, and in vitro drug release.
Results: Faster dissolution rate was exhibited by SD containing 1:5 ratio of celecoxib: PVP K-30 prepared by coevaporation method. In vitro drug 
release of celecoxib, gels revealed that formulation with HPMC has higher drug release as compared to Carbopol.
Conclusion: The increase in dissolution rate for SD is observed in the following order of PVP K-30>urea>mannitol>PEG 6000. The CPD5 gel containing 
a SD CP5 and 20% DMSO showed the best in vitro release 74.13% at the end of 6 h.
Keywords: Celecoxib, Solid dispersion, Solid dispersion incorporated gels, Hydroxypropyl methyl cellulose K4M, In vitro drug release.
INTRODUCTION
Solubility is an important physicochemical factor which affects the 
absorption of drugs and, in turn, affects its therapeutic effectiveness. 
According to the biopharmaceutics classification system, drugs with low 
aqueous solubility and high membrane permeability are categorized as 
Class II drugs. Solid dispersion (SD) method involves dispersion of the 
drug in the extremely fine state in an inert water-soluble carrier in the 
solid state [1].
The USP defines gels as semisolid systems consisting of either 
suspension made up of small inorganic particles or large organic 
molecules interpenetrated by liquid. Some important polymers used to 
prepare pharmaceutical gels include natural gums such as tragacanth, 
pectin, carrageenan, agar, and alginic acid, and synthetic and 
semisynthetic materials such as methyl cellulose, hydroxyethylcellulose, 
and carboxymethyl cellulose [1].
Rheumatoid arthritis (RA) is an autoimmune disease causing chronic 
inflammation of the joints. RA shows inflammation of the tissue around 
the joints and inflammatory arthritis as characteristic features. The 
disease can also cause inflammation and injury in other organs in the 
body [3]. Aspirin and cortisone (corticosteroids) are first-line drugs, used 
to reduce pain and inflammation. The slow-acting second-line drugs, 
such as methotrexate (Rheumatrex and trexall), and hydroxychloroquine 
(plaquenil), promote disease remission, and prevent joint destruction. 
Celecoxib (Celebrex), a newer nonsteroidal anti-inflammatory drug 
showing selective COX-2 inhibitor action, offers anti-inflammatory 
effects with less risk of stomach irritation and bleeding risk [2].
Celecoxib shows poor aqueous solubility (3 µg/ml) which is major 
drawback. Incomplete absorption of celecoxib from the gastrointestinal 
tract results in poor water solubility, in turn, showing low 
bioavailability [2]. Celecoxib has a very low oral bioavailability of just 
about 40%. It is reported that oral formulations of celecoxib can cause 
gastric mucosal damage, which may result in ulceration and bleeding, 
stomatitis, duodenal perforations, blood clots leading to fatal heart 
attacks, and strokes. These side effects are rare but very fatal.
Therefore, there is a need to develop topical dosage forms of celecoxib 
to minimize the gastrointestinal side effects of oral celecoxib and 
to provide relatively consistent drug levels at the application site for 
prolonged periods. This study aims to apply the SD method using 
mannitol, polyvinylpyrrolidone (PVP-K30), polyethylene glycol (PEG) 
6000, and urea as carriers, and study the dissolution behavior as well 
as the increase in aqueous solubility of celecoxib thereby proving the 
efficiency of the SD method [4].
The present study aims to study the release rate of topically 
administered celecoxib with a novel approach using SD incorporated 
gels in the presence and absence of permeability enhancer.
MATERIALS AND METHODS
Materials
Celecoxib was obtained from Unichem Laboratories Ltd., 
polyvinylpyrrolidone K-30 from Geno Pharmaceuticals, PEG 6000, and 
sodium lauryl sulfate from HiMedia Laboratories Pvt. Ltd., mannitol 
from Loba Chemie Pvt., Ltd., and urea from Molychem as gift sample. All 
reagents used were of analytical grade.
Methodology
Preparation of calibration curve of celecoxib in methanol, distilled 
water with 1%SLS, and phosphate buffer pH 7.4
A standard stock solution containing 100 µg/ml was prepared in 
methanol. From the working standard solution, concentrations of 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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2–20 µg/ml were prepared by dilution with methanol, distilled water 
with 1% SLS, and phosphate buffer pH 7.4. The calibration curve for 
celecoxib was plotted on concentration versus absorbance at 254 nm 
on PerkinElmer Lambda 25 UV/VIS Spectrometer. Regression 
analysis was performed, and the concentration of celecoxib was 
determined [2].
Compatibility studies between the drug and excipients by infrared 
(IR) spectroscopy:
The IR absorption spectrum was obtained by preparing a simple 
physical mixture of the drug and the carrier/excipient [3,4]. The 
mixture was then placed on the stage of the instrument and scanned by 
the passage of an IR beam through it. The spectra were scanned over a 
frequency range 4000–600 cm−1.
Preparation of SDs:
SDs were prepared by various polymers and different methods as 
shown in Table 1.
Solvent evaporation method
The required amount of celecoxib and carrier in 1:1, 1:3, and 1:5 ratios 
was dissolved in a sufficient volume of methanol with continuous 
stirring. The solvent from solution was removed at 45°C by continuous 
stirring to obtain a dry mass. The dried mass was pulverized, passed 
through 44 mesh sieve and stored in a desiccator [5,6].
Fusion method
Accurately weighed the amount of carrier was melted in a porcelain 
dish at 80–85°C and to this calculated amount of celecoxib was added 
with thorough mixing for 1–2 min followed by quick cooling. The dried 
mass was pulverized, passed through 44 mesh sieve and stored in a 
desiccator [5,6].
Coevaporation method
Celecoxib is dissolved in methanol and carrier in aqueous media. 
Subsequently, the organic drug solution is slowly added to the aqueous 
carrier solution followed by stirring at 300 rpm using a magnetic stirrer 
at 37°C for 24 h. Resultant SD is passed through a 120 mesh sieve [5,7,8].
The prepared SDs were evaluated for its physical appearance, percent 
practical yield, and drug content analysis.
In vitro dissolution study
The release of the drug in vitro was determined by estimating the 
dissolution profile. Regression analysis was performed and celecoxib 
concentration was determined [9].
Aqueous solubility studies
The aqueous solubility analysis was performed on the SDs by adding 
an excess amount of the SD, that is, 50 mg to 10 ml of distilled water 
in a stoppered conical flask and shaken using a rotary shaker at room 
temperature for 24 h. An aliquot was withdrawn and was filtered 
through Whatman filter paper no.40. The filtrate was analyzed for drug 
concentration by UV [9].
Differential scanning colorimetry (DSC) analysis
DSC studies were carried out in which samples were examined using a 
Mettler Toledo (DSC 823) instrument. 3–4 mg of samples was weighed 
into an aluminum pan and sealed with a lid having a pinhole in the 
center. Sealed pan-lid is then loaded on DSC instrument and heated 
from 25°C to 200°C at a heating rate of 10°C/min. Nitrogen was used as 
the purge gas for the instrument [7].
Scanning electron microscopy (SEM) studies
SEM studies were performed using TM3000 tabletop microscope. The 
prepared slides were loaded one by one into this instrument which gave 
the SEM images of the sample at the desired magnification [7].
X-ray diffraction (XRD) studies
The SDs were subjected to XRD studies to study any changes in the 
solid state of the drug. The samples of SD were analyzed using the 
Bruker D8 Advance powder XRD instrument. The samples were 
Table 1: Formulation ingredients, preparation method of celecoxib SDs
Batch code Composition Method Ratio (Drug: Carrier)
SP1 Celecoxib+PVP K-30 Solvent Evaporation 1:1
SP3 Celecoxib+PVP K-30 Solvent Evaporation 1:3
SP5 Celecoxib+PVP K-30 Solvent Evaporation 1:5
SG1 Celecoxib+PEG 6000 Solvent Evaporation 1:1
SG3 Celecoxib+PEG 6000 Solvent Evaporation 1:3
SG5 Celecoxib+PEG 6000 Solvent Evaporation 1:5
SU1 Celecoxib+Urea Solvent Evaporation 1:1
SU3 Celecoxib+Urea Solvent Evaporation 1:3
SU5 Celecoxib+Urea Solvent Evaporation 1:5
FG1 Celecoxib+PEG 6000 Fusion method 1:1
FG3 Celecoxib+PEG 6000 Fusion method 1:3
FG5 Celecoxib+PEG 6000 Fusion method 1:5
FU1 Celecoxib+Urea Fusion method 1:1
FU3 Celecoxib+Urea Fusion method 1:3
FU5 Celecoxib+Urea Fusion method 1:5
FM1 Celecoxib+Mannitol Fusion method 1:1
FM3 Celecoxib+Mannitol Fusion method 1:3
FM5 Celecoxib+Mannitol Fusion method 1:5
CP1 Celecoxib+PVP K-30 Coevaporation method 1:1
CP3 Celecoxib+PVP K-30 Coevaporation method 1:3
CP5 Celecoxib+PVP K-30 Coevaporation method 1:5
CG1 Celecoxib+PEG 6000 Coevaporation method 1:1
CG3 Celecoxib+PEG 6000 Coevaporation method 1:3
CG5 Celecoxib+PEG 6000 Coevaporation method 1:5
CU1 Celecoxib+Urea Coevaporation method 1:1
CU3 Celecoxib+Urea Coevaporation method 1:3
CU5 Celecoxib+Urea Coevaporation method 1:5
CM1 Celecoxib+Mannitol Coevaporation method 1:1
CM3 Celecoxib+Mannitol Coevaporation method 1:3
CM5 Celecoxib+Mannitol Coevaporation method 1:5
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packed as such in the powder XRD sample holder using a glass slide, 
loaded on the instrument. The instrument was run over a scan range 
of 2°–50° (2θ) [7].
Preparation of celecoxib SD incorporated gels
Preparation of gels
Gels were prepared using two polymers, Carbopol 971P, and HPMC 
K4M as shown in Table 2. The polymer and purified water were taken in 
a mortar and allow soaking for 24 h. The SD was weighed and dissolved 
in water. It was slowly added to the soaked polymer and triturated well 
after each addition to get a homogenous dispersion of the drug in the 
gel. Propylene glycol was then added, and the trituration was continued.
Permeation enhancer - dimethyl sulfoxide (DMSO) was incorporated in 
different concentrations (1–30%) into the gel.
Formulation of celecoxib gel with permeation enhancer - DMSO
Evaluation of celecoxib SD incorporated gels
Physical appearance and homogeneity
Gel formulation containing celecoxib was visually inspected for clarity, 
color, homogeneity, and the presence of particles and fibers [10].
Determination of pH
Digital pH meter was used to check the pH of gels at room temperature. 
Initially, the pH meter was calibrated using standard buffers of pH 4 
and pH 9.2. Accurately, 2.5 g of gel was weighed and dispersed in 25 ml 
purified water and pH of this dispersion was noted [10,11].
The drug content of the prepared gels was carried out by dissolving 
accurately weighed quantity of gel equivalent to 10 mg of the drug 
was dissolved in 10 ml methanol. The volume was made up to 
100 ml, and 5 ml of the above solution was further diluted to 25 ml 
with methanol. After suitable dilution absorbance of the solution 
was recorded using PerkinElmer Lambda 25 UV/VIS Spectrometer 
at 252.5 nm.
Spreadability
Spreadability of gel formulations was determined by an apparatus 
suggested by Mortimer et al., which was suitably modified and used for 
the study. The spreadability was calculated using the formula
S=m.l/t
Table 2: Preparation of gels containing SD CP5 in HPMC and 
Carbopol gels
Ingredients HPMC gel (%) Carbopol gel (5)
Celecoxib SD 2 2
HPMC K4M 10 -
Carbopol 971P - 1
Propylene glycol 10 10
Triethanolamine - 0.5
Purified water q.s 100 q.s 100
Ingredients CPD1 (%) SPD1 (%) CPD2 (%) CPD3 (%) CPD4 (%) CPD5 (%) CPD6 (%)
Celecoxib SD 2 2 2 2% 2 2 2
HPMC K4M 10 10 10 10 10 10 10
DMSO 1 1 5 10 15 20 30
Propylene glycol 10 10 10 10 10 10 10
Purified water q. s 100 q. s 100 q. s 100 q. s 100 q. s 100 q. s 100 q. s 100
Formulation code Drug content (%) % practical yield Color Physical appearance
SP1 96.60 94.75 Off white Powder (granular)
SP3 96.18 90.62 Off white Powder (granular)
SP5 95.98 88.00 Off white Powder (granular)
SG1 98.25 89.50 White Fine Powder
SG3 97.24 84.50 White Fine Powder
SG5 96.82 88.56 White Fine Powder
SU1 96.80 92.75 White Fine Powder
SU3 96.40 93.12 White Fine Powder
SU5 95.70 93.00 White Fine Powder
FG1 97.26 87.50 White Fine Powder
FG3 96.54 92.25 White Fine Powder
FG5 95.48 88.91 White Fine Powder
FU1 96.10 90.62 White Fine Powder
FU3 96.02 93.06 White Fine Powder
FU5 95.12 92.34 White Fine Powder
FM1 96.18 95.80 White Fine Powder
FM3 95.44 93.62 White Fine Powder
FM5 95.32 94.00 White Fine Powder
CP1 96.44 94.00 White creamy Fine Powder
CP3 96.88 95.00 White creamy Fine Powder
CP5 97.88 95.83 White creamy Fine Powder
CG1 97.86 83.50 White Fine Powder
CG3 97.62 84.50 White Fine Powder
CG5 96.40 82.50 White Fine Powder
CU1 96.02 90.87 White Fine Powder
CU3 95.64 88.75 White Fine Powder
CU5 2.67 88.58 White Fine Powder
CM1 2.72 89.87 White Fine Powder
CM3 2.71 84.76 White Fine Powder
CM5 2.69 89.16 White Fine Powder
Table 4: Drug content uniformity, percentage practical yield, and physical appearance of celecoxib SDs
Table 3: Preparation of gels containing SD and permeation enhancer - DMSO
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Where, S is spreadability, m is the weight tied to the upper slide, l is the 
length of the glass slide, and t is the time taken [6].
Extrudability
The evaluation of gel formulation for extrudability was based on 
the quantity of gel (in percentage) extruded from the tube on the 
application of a certain load. The formulation under study was filled 
with a clean, lacquered aluminum collapsible 10 g tube with a nasal tip 
of 5 mm opening. It was placed in between two glass slides and was 
clamped. Extrudability was determined by weighing the amount of gels 
extruded through the tip when a constant load of 1 kg was placed on 
the slides and gels extruded was collected and weighed. The percentage 
of gel extruded was calculated and grades were allotted. (++: Good, +: 
fair) [12].
In vitro diffusion study
The apparatus consists of a glass cylinder with both the ends open. A 
dialysis membrane was fixed to one end of the cylinder with the aid of 
an adhesive. Gels equivalent to 3.33 mg of celecoxib were taken inside 
the cell (donor compartment), and the cell was immersed in a beaker 
containing 100 ml 7.4 pH phosphate buffer (receptor compartment). 
The medium in the compartment was agitated using a magnetic stirrer 
at a temperature 37°C±1°C. Aliquots (5 ml) were withdrawn from the 
receptor compartment periodically at an interval of 30 min up to 6 h 
and replaced with 5 ml of fresh buffer. After suitable dilution, the sample 
was analyzed using PerkinElmer Lambda 25 UV/VIS Spectrometer at 
248 nm [13, 17].
Stability studies
The selected gel formulation was kept at two different temperature 
conditions, that is, 30±2°C and 5±2°C of accelerated stability testing 
for a period of 90 days, after which parameters such as color, pH, 
spreadability, extrudability, drug content, and in vitro drug release were 
studied [14,15].
RESULTS
Sr. No. Formulation code Physical appearance Homogeneity pH % Drug content
1 Carbopol gel white translucent ++ 6.71 95.80±1.43
2 HPMC gel white translucent ++ 6.52 96.46±1.41
3 CPD1 white translucent ++ 6.92 96.85±1.38
4 SPD1 white translucent ++ 7.10 95.10±1.15
5 CPD2 white translucent ++ 6.34 96.49±1.43
6 CPD3 white translucent ++ 6.76 96.22±1.37
7 CPD4 white translucent ++ 7.04 96.51±1.31
8 CPD5 white translucent ++ 6.86 97.03±1.42
9 CPD6 white translucent ++ 6.54 95.72±1.40
++: good; +: fair. mean±SD, n=3








Fig. 1. Comparison of percentage cumulative drug release of celecoxib from solid dispersions prepared by (a) fusion method, (b) solvent 
evaporation method, and (c) coevaporation method, respectively
c
ba
Drug content uniformity, percentage practical yield, and 
physical appearance of celecoxib SDs
Dissolution studies
Table 5: Solubility measurements of celecoxib pure drug and its 
SDs
Table 6: Physical parameters, drug content of the formulations
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Evaluation of celecoxib solid dispersion incorporated gels
Physical parameters and drug content of the formulations
Standard calibration curve of celecoxib
Standard plot of drug concentrations from 0 to 20 µg/ml was 
obtained. The straight line equations and regression coefficients 
obtained for methanol, 1% SLS in distilled water and buffer pH 7.4 are 
y=0.0055x, R²=0.999; y=0.056x, R²=0.999; and y=0.060x, R²=0.999, 
respectively.
Percent practical yield
The percentage practical yield of the prepared SDs was found 
to be in the range of 80.37–95.83%. The maximum yield was 
found to be 95.83% in SD CP5 containing 1:5 ratio of celecoxib: PVP 
K-30.
S. No. Formulation code Spreadability (g-cm/s) Extrudability
1 Carbopol gel 11.40 ++
2 HPMC gel 12.35 ++
3 CPD1 13.40 ++
4 SPD1 11.50 +
5 CPD2 14.90 ++
6 CPD3 11.70 ++
7 CPD4 12.60 +
8 CPD5 14.15 ++
9 CPD6 13.80 +
++: Good; +: Fair 
Temperature CPD5 gel
Drug content (%) In vitro diffusion study (%) in 6 h pH Spreadability Extrudability
30±2°C 96.94±1.43 73.97 6.80 14.10 ++
5±2°C 97.01±1.38 73.89 6.78 14.35 ++
mean±SD, n=3







Table 7: Rheological properties of the formulations
Table 8: Stability studies data for optimized gel formulation 
Fig. 2. Overlay of DSC thermogram of celecoxib and its solid dispersions
Fig. 3. Overlay of X-ray diffractogram of celecoxib and its solid dispersions
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Compatibility studies between celecoxib and excipients by IR 
spectroscopy
No interaction was observed when celecoxib and carriers/excipients 
mixture was tested.
Drug content
The drug content of the prepared SDs was found to be in the range of 
95.12–97.88% indicating that the application of the present methods 
for the preparation of SDs gave high content uniformity.
Dissolution studies
Release of Celecoxib from SDs was found to be faster than the pure 
drug itself. The reason for the poor dissolution of the pure drug could 
be poor wettability and agglomeration of particles. In the case of SDs 
probably the affinity of the hydrophilic inert carriers to the dissolution 
fluid facilitates rapid penetration into the particles, enhancing the 
dissolution process.




The in vitro drug release data of the selected SDs-CU5, CM1, CP5, SP5, 
and SU1 were treated to first-order, Higuchi diffusion plot, and Peppa’s 
exponential plot. The R values for first-order plots were significantly 
higher as compared to zero-order plots which indicate that all the 
formulations best fitted in first-order kinetics and poorly fitted in zero-
order kinetics. The first-order plot was found to be fairly linear, indicating 
that the drug release followed first-order kinetics; with SD CP5 showing 
the highest R2=0.993. Similarly, the data were treated according to 
Higuchi’s diffusion equation. The best fit with higher correlation was 
found with the Higuchi’s equation for most of the formulations with the 
highest correlation coefficient (R2=0.989) for SD CP5. The result indicated 
that all formulations exhibited diffusion mechanism in drug release. 
Further, the data were subjected to Peppa’s model where the R value 
revealed that the Peppa’s model best fitted in all dissolution profiles. 
Peppa’s exponential plot gave slope values <0.5 for SDs CU5 (0.081), 
CM1 (0.138), and SU1 (0.425) indicating that the drug release followed 
Fick’s law of diffusion, while the slope values for SDs SP5 (0.731) and CP5 
(0.637) were >0.5 indicating non-Fickian diffusion process.
Aqueous solubility studies
The solubility studies show a solubilizing effect of the carrier used 
which remarkably enhance the aqueous solubility of celecoxib. The 
efficiency of the carriers used in increasing the solubility of celecoxib 
thereby follows the order:
PVP K-30>Urea>mannitol>PEG 6000
DSC studies
The pure drug celecoxib subjected to DSC study started melting at 
161.85°C and completed at 166.31°C. The DSC thermogram of celecoxib 
showed a sharp endothermic peak at 163.42°C corresponding to its 
melting point, indicating its crystalline nature. It suggests the presence 
of a single compound in the pure form. Due to the absence of the 
endothermic peak of celecoxib in the SDs SP5, DSC studies reveal that 
celecoxib drug was no longer present in crystalline form and probably 
molecularly dispersed in amorphous form in the polymeric matrix of 
PVP K-30. The increase in the solubility of celecoxib could, therefore, be 
attributed to its conversion in the amorphous form.
XRD
The XRD studies show the conversion of the crystalline form of drug into 
amorphous form and hence, increases the solubility. These assumptions 
were found to be in full agreement with the results presented by the 
DSC studies.
SEM studies
In the SEM image of celecoxib, the drug crystals are seen as flat, blunt-
ended tabular shaped crystals of various sizes. The SEM image of SD 
CP5 shows celecoxib drug particles uniformly dispersed throughout, 
wherein some of the drug crystals have lost their original tabular 






Fig. 4. SEM image of solid dispersion (a) pure drug celecoxib, (b) solid dispersion CM1, (c) SU1, (d) CU5, (e) SP5, and (f) CP5, respectively
Fig. 5. In vitro drug release profile of celecoxib from formulated 
gels
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amorphous material and that there is also the formation of crystalline 
microaggregates of the drug and their considerable dispersions within 
the amorphous polymeric matrices of PVP K-30.
On the basis of all the above studies, increase in aqueous solubility being 
the main reason, SD CP5, and SP5, were selected for incorporation into 
gels using Carbopol 971P and HPMC as gelling agents.
SD CP5 was first used to prepare gels with Carbopol 971P and 
HPMC so as to arrive at the gelling agent giving better release of 
celecoxib from the gels. The in vitro diffusion study revealed that 
HPMC was more suitable to provide a better release of celecoxib with 
a percentage CR of 46.66% as compared to that of Carbopol with a 
percentage CR of 42.64% after 6 h. Hence, HPMC was chosen to be 
used for the preparation of SP5 incorporated gel and to study the 
effect of incorporation of permeation enhancer - DMSO into the gels. 
The SPD1 gel containing a SD SP5 and 1% DMSO was subjected to 
in vitro diffusion study and the in vitro percentage drug release of 
celecoxib was compared with that of CPD1 gel containing a SD CP5 
and 1% DMSO. The study showed that CPD1 gel gave better release 
of celecoxib with a percentage CR of 50.43% as compared to that of 
SPD1 gel with a percentage CR of 48.22% after 6 h. Therefore, SD 
CP5 was chosen for study of the effect of incorporation of permeation 
enhancer - DMSO on the in vitro release of celecoxib from the gels. The 
concentration of DMSO used for the study was 1–30%.
Gel formulations showed good extrudability and homogeneity. All the 
formulations were found to have good spreadability. The pH of all the 
formulations was between 6.34 and 7.10. This lies in the normal pH 
range of the skin. The drug content was in the range of 94.32–99.03%.
Fig. 5 depicts the in vitro diffusion profile of celecoxib from gels 
containing a SD CP5 and different concentration of permeation 
enhancer DMSO over a period of 6 h. It also depicts that 20% of dimethyl 
sulfoxide released a maximum of 74.13% of celecoxib within a period of 
6 h. Further increase in DMSO concentration to 30% showed no further 
increase in drug release. Among all gel formulations, the highest release 
of celecoxib was given by CPD5 gel, that is, 74.13%. The pure drug and 
showed a cumulative percent release of 23.95%.
Statistical analysis
The data obtained from the plots were subjected to linear regression 
analysis. The models that best fit the data were evaluated by the 
correlation coefficient (R). The R values for first-order plots were 
significantly lower as compared to zero-order plots which indicate that 
all the formulations best fitted in zero-order kinetics and poorly fitted in 
first-order kinetics. The zero-order plots were found to be fairly linear 
indicating the drug release, follows zero-order kinetics. The best fit with 
higher correlation was found with the Higuchi’s equation for most of 
the formulations. The Higuchi diffusion plot was also linear, indicating 
that the drug release was diffusion controlled. Further, the data were 
subjected to Peppa’s model where the R value revealed that the Peppa’s 
model best fitted in all diffusion profiles. Peppa’s exponential plot gave 
slope values <0.5 for all the gel formulations indicating that the drug 
release followed Fick’s law of diffusion.
Based on the analysis and comparison of the results of all the evaluation 
tests of all gel formulations, an ideal optimized formulation was 
selected which gave satisfactory results for all evaluation tests which 
is a prerequisite for successful utilization of this dosage form. CPD5 gel 
was selected as the optimized formulation.
Stability studies
Stability studies revealed that formulated gel is stable.
CONCLUSION
The dissolution rate of celecoxib of SD was significantly higher than that 
of pure drug. SD prepared by coevaporation method showed a faster 
drug release than the dispersion prepared by solvent evaporation 
method followed by fusion method. The general trend indicated that 
there was an increase in dissolution rate for SD in the following order 
of PVP K-30 > urea > mannitol >PEG 6000. From all formulations, CPD5 
gel, which was formulated using HPMC polymer and containing the SD 
CP5 with 20% DMSO was found to be the best formulation.
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